CNX Therapeutics CEO Guy Clark Awarded “CEO of the Year” at CPHI Pharma Awards

LONDON, October 10^th 2024, - CNX Therapeutics Limited (“CNX Therapeutics”), a speciality  pharmaceutical company dedicated to improving the lives of patients through the supply of essential medicines, today announced that CEO Guy Clark was named “CEO of the Year” at the 2024 CPHI Pharma Awards, a top pharmaceutical event uniting over 62,000 professionals worldwide.

The 2024 CPHI Pharma Awards recognise the innovation and dedication of companies and individuals who are driving the pharmaceutical industry forward. Its Judging Panel is comprised of independent, senior industry experts, each chosen for their knowledge, objectivity and credibility. This year’s awards gala took place on October 8 in Milan, Italy.

Guy was chosen for spearheading CNX’s growth over the past 12 months. Under his leadership since joining as CEO in January 2022, CNX has transformed from a single-product unit into a standalone business with a portfolio of more than 30 products. His tenure at CNX has been marked by significant expansion into new European markets including France and the Nordics. He has also led sustainability initiatives including a B-Corp application, positioning CNX to be one of the first pharmaceutical companies to achieve this certification.

Commenting on the achievement, Guy Clark, CEO of CNX Therapeutics, said: "This award is a tremendous honour and a true reflection of our exceptional team's dedication at CNX Therapeutics. I'm grateful to our partners and everyone who has supported us to achieve so much in a short period of time. I’m excited about the path ahead as we continue our mission to become Europe's partner of choice for established brands and value-added medicines."

Guy has also been shortlisted as a finalist in the Scrip Awards, in the “Executive of the Year" category. The Scrip Awards ceremony takes place in London on 4 December 2024.

CNX Therapeutics was acquired by Inflexion Private Equity, a leading mid-market private equity firm, in 2021.